查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1604747

自閉症頻譜市場：按產品類型、藥物、分銷分類 - 全球預測 2025-2030

Autism Spectrum Disorders Market by Product Type (Aripiprazole, Balovaptan, Bumetanide), Drug (Anticonvulsants, Antipsychotics, Selective Serotonin Reuptake Inhibitors), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

自閉症頻譜市場2023年估值為5.4426億美元，預計到2024年將達到5.7718億美元，複合年成長率為6.14%，預計到2030年將達到8.2612億美元。

自閉症頻譜(ASD) 涵蓋一系列神經發育障礙，其特徵是社交互動、溝通和重複行為的挑戰。自閉症譜系障礙盛行率不斷上升，每44 名確診患者中就有1 人受到自閉症譜系障礙的影響，這凸顯了對治療、教育和支持干預措施的迫切需要，因此需要更深入地了解自閉症譜系障礙。應用範圍包括醫療診斷、製藥、行為治療和專業教育工具，最終用途包括醫院、學校、研究機構和復健中心。關鍵的成長要素包括早期診斷意識的提高、診斷方法的技術進步以及政府資助的增加。例如，利用人工智慧進行早期檢測和個人化治療計劃顯示出巨大的潛力。最近的商機在於遠端醫療平台，該平台促進遠距評估和治療會議，提供便利和廣泛的覆蓋範圍。然而，治療成本上升、缺乏訓練有素的專業人員以及獲得優質治療的社會經濟障礙阻礙了市場成長。文化偏見和監管挑戰也使這些問題變得複雜，限制了更廣泛的接受和實施。技術創新的機會傾向於開發具有成本效益的診斷工具、增強數位療法以及利用基因組研究來更好地了解自閉症譜系障礙的病因和多樣性。透過以適應性強、低成本的產品進入新興市場，公司可以吸引服務不足的人。由於市場競爭激烈且分散，主要企業都專注於內部成長和收購主導的成長策略，以擴大其產品範圍。公司應與研究機構建立策略夥伴關係，以維持創新曲線的領先地位，並考慮與非營利組織建立夥伴關係，以加強社區推廣和支援服務。未來，個人化醫療和整合多種治療方法的整體方法的創新可能成為競爭前沿，為自閉症譜系障礙患者提供更全面的解決方案。

主要市場統計
基準年[2023] 5.4426億美元
預計年份 [2024] 57718萬美元
預測年份 [2030] 8.2612億美元
複合年成長率（%） 6.14%

市場動態：揭示快速發展的自閉症頻譜市場的關鍵市場洞察

自閉症頻譜市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • ASD 患者增加
    • 增加政府資助的自閉症意識項目
    • 改善自閉症篩檢和診斷
  • 市場限制因素
    • 關於產品核可的嚴格規定
  • 市場機會
    • 加大研發治療自閉症譜系障礙的有效藥物
    • 臨床試驗中新的自閉症治療方法的出現
  • 市場挑戰
    • 缺乏診斷自閉症的專家

波特五力：駕馭自閉症頻譜市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解自閉症頻譜市場的外部影響

外部宏觀環境因素在塑造自閉症頻譜市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解自閉症頻譜市場的競爭格局

自閉症頻譜市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣自閉症頻譜市場供應商績效評估

FPNV定位矩陣是評估自閉症頻譜市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製自閉症頻譜市場的成功之路

自閉症頻譜市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：全面分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 自閉症頻譜(ASD) 患者盛行率不斷增加
      • 增加政府資助的自閉症意識項目
      • 改善自閉症篩檢和診斷
    • 抑制因素
      • 關於產品核可的嚴格規定
    • 機會
      • 擴大 ASD 治療有效藥物的研發活動
      • 臨床試驗中新的自閉症治療方法的出現
    • 任務
      • 缺乏診斷自閉症的專家
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章自閉症頻譜市場：依產品類型

  • Aripiprazole
  • Balovaptan
  • Bumetanide
  • CM-AT
  • 褪黑素
  • Risperidone

第7章自閉症頻譜藥物市場

  • 抗驚厥藥
  • 抗精神病藥
  • 選擇性血清素再回收抑制劑

第8章 自閉症頻譜市場經銷商

  • 醫院
  • 零售藥房

第9章美洲自閉症頻譜市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區自閉症頻譜市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲自閉症頻譜市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Curemark, LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Hopebridge, LLC
  • Intra-Cellular Therapies, Inc.
  • Jazz Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Neurim Pharmaceuticals Ltd.
  • Novartis AG
Product Code: MRR-436901065E81

The Autism Spectrum Disorders Market was valued at USD 544.26 million in 2023, expected to reach USD 577.18 million in 2024, and is projected to grow at a CAGR of 6.14%, to USD 826.12 million by 2030.

Autism Spectrum Disorders (ASD) encompass a range of neurodevelopmental conditions characterized by challenges in social interaction, communication, and repetitive behaviors. The necessity for a deep understanding of ASD arises from its increasing prevalence, with one in every 44 children diagnosed, highlighting urgent needs in therapeutic, educational, and supportive interventions. Applications span across healthcare diagnostics, pharmaceuticals, behavioral therapy, and specialized educational tools, while the end-use scope includes hospitals, schools, research institutions, and rehabilitation centers. Key growth factors include rising awareness about early diagnosis, technological advancements in diagnostic methodologies, and increased governmental funding. For instance, the use of Artificial Intelligence for early detection and personalized treatment plans has showcased significant potential. Recent opportunities lie in telehealth platforms which facilitate remote assessments and therapy sessions, offering convenience and broader reach. However, market growth is hampered by high costs of treatment, scarcity of trained professionals, and socio-economic barriers in accessing quality care. Cultural stigma and regulatory challenges further compound these issues, limiting broader acceptance and implementation. Opportunities for innovation lean towards developing cost-effective diagnostic tools, enhancing digital therapeutics, and leveraging genomic research to better understand ASD etiology and variance. Entering emerging markets with adaptable, low-cost products can enable firms to capture underserved demographics. The nature of the market is competitive and fragmented, with key players focused on both organic and acquisition-led growth strategies to expand their offerings. Companies should form strategic partnerships with research institutions to stay ahead in the innovation curve and consider collaborations with non-profits to enhance community outreach and support services. Moving forward, innovation in personalized medicine and holistic approaches integrating multiple therapies could define the competitive frontier, enabling more inclusive solutions for individuals with ASD.

KEY MARKET STATISTICS
Base Year [2023] USD 544.26 million
Estimated Year [2024] USD 577.18 million
Forecast Year [2030] USD 826.12 million
CAGR (%) 6.14%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Autism Spectrum Disorders Market

The Autism Spectrum Disorders Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of patients with autism spectrum disorders (ASD)
    • Rise in government-sponsored awareness programs for autism
    • Improvements in autism screening and diagnostics
  • Market Restraints
    • Stringent regulations on product approval
  • Market Opportunities
    • Growing research & development activities for effective drugs for the treatment of ASD
    • Emergence of new autism medications undergoing clinical trials
  • Market Challenges
    • Lack of autism specialists to diagnose the disorder

Porter's Five Forces: A Strategic Tool for Navigating the Autism Spectrum Disorders Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Autism Spectrum Disorders Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Autism Spectrum Disorders Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Autism Spectrum Disorders Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Autism Spectrum Disorders Market

A detailed market share analysis in the Autism Spectrum Disorders Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Autism Spectrum Disorders Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Autism Spectrum Disorders Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Autism Spectrum Disorders Market

A strategic analysis of the Autism Spectrum Disorders Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Autism Spectrum Disorders Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Curemark, LLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Hopebridge, LLC, Intra-Cellular Therapies, Inc., Jazz Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Mylan N.V., Neurim Pharmaceuticals Ltd., and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Autism Spectrum Disorders Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Aripiprazole, Balovaptan, Bumetanide, CM-AT, Melatonin, and Risperidone.
  • Based on Drug, market is studied across Anticonvulsants, Antipsychotics, and Selective Serotonin Reuptake Inhibitors.
  • Based on Distribution, market is studied across Hospitals and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of patients with autism spectrum disorders (ASD)
      • 5.1.1.2. Rise in government-sponsored awareness programs for autism
      • 5.1.1.3. Improvements in autism screening and diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations on product approval
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing research & development activities for effective drugs for the treatment of ASD
      • 5.1.3.2. Emergence of new autism medications undergoing clinical trials
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of autism specialists to diagnose the disorder
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Autism Spectrum Disorders Market, by Product Type

  • 6.1. Introduction
  • 6.2. Aripiprazole
  • 6.3. Balovaptan
  • 6.4. Bumetanide
  • 6.5. CM-AT
  • 6.6. Melatonin
  • 6.7. Risperidone

7. Autism Spectrum Disorders Market, by Drug

  • 7.1. Introduction
  • 7.2. Anticonvulsants
  • 7.3. Antipsychotics
  • 7.4. Selective Serotonin Reuptake Inhibitors

8. Autism Spectrum Disorders Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Retail Pharmacies

9. Americas Autism Spectrum Disorders Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Autism Spectrum Disorders Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Autism Spectrum Disorders Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AstraZeneca PLC
  • 3. Bristol-Myers Squibb Company
  • 4. Curemark, LLC
  • 5. Eli Lilly and Company
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Hopebridge, LLC
  • 8. Intra-Cellular Therapies, Inc.
  • 9. Jazz Pharmaceuticals, Inc.
  • 10. Johnson & Johnson Services, Inc.
  • 11. Merck & Co., Inc.
  • 12. Mylan N.V.
  • 13. Neurim Pharmaceuticals Ltd.
  • 14. Novartis AG

LIST OF FIGURES

  • FIGURE 1. AUTISM SPECTRUM DISORDERS MARKET RESEARCH PROCESS
  • FIGURE 2. AUTISM SPECTRUM DISORDERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AUTISM SPECTRUM DISORDERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. AUTISM SPECTRUM DISORDERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AUTISM SPECTRUM DISORDERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AUTISM SPECTRUM DISORDERS MARKET DYNAMICS
  • TABLE 7. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY ARIPIPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY BALOVAPTAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY BUMETANIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY CM-AT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY MELATONIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY RISPERIDONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM AUTISM SPECTRUM DISORDERS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM AUTISM SPECTRUM DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 148. AUTISM SPECTRUM DISORDERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. AUTISM SPECTRUM DISORDERS MARKET, FPNV POSITIONING MATRIX, 2023